Parabilis Medicines, Inc. filed a Current Report on Form 8-K with the SEC on August 13, 2026, announcing its financial results and business highlights for the quarter ended June 30, 2026, and furnishing an updated corporate presentation under Regulation FD.

Key Highlights

  • Quarterly results announced: The company disclosed financial results and business highlights for the quarter ended June 30, 2026.
  • Press release furnished: A press release dated August 13, 2026, was attached as Exhibit 99.1 to the filing.
  • Corporate presentation updated: An updated investor presentation dated August 2026 was furnished as Exhibit 99.2 under Regulation FD.
  • Emerging growth company: Parabilis Medicines, Inc. is designated as an emerging growth company under applicable SEC rules, according to the filing.
  • Signed by CFO: The filing was signed by Thomas Kotarakos, Chief Financial Officer, on August 13, 2026.

Parabilis Medicines Furnishes Q2 2026 Results and Updated Investor Materials

Parabilis Medicines, Inc. (NASDAQ:PBLS), a Delaware-incorporated biopharmaceutical company headquartered at 30 Acorn Park Drive, Cambridge, Massachusetts, filed this Current Report to communicate its second-quarter financial performance. According to the filing, the company announced its financial results and business highlights for the quarter ended June 30, 2026, with the full details contained in a press release furnished as Exhibit 99.1.

Under Item 7.01, the filing discloses that the company also updated its corporate presentation, intended for use in meetings with investors, analysts, and others from time to time. That presentation, dated August 2026, was furnished as Exhibit 99.2. The filing notes that the information provided under both Item 2.02 and Item 7.01 is being "furnished" rather than "filed," meaning it is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.

The company identified itself as an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. Parabilis Medicines also indicated it has not elected to use the extended transition period for complying with new or revised financial accounting standards. The report carries Commission File Number 001-43331 and IRS Employer Identification Number 47-4505725. Thomas Kotarakos, serving as Chief Financial Officer, signed the filing on behalf of the registrant.

What Was Disclosed

Parabilis Medicines, Inc. furnished an 8-K on August 13, 2026, covering its Q2 2026 financial results via a press release (Exhibit 99.1) and an updated corporate investor presentation (Exhibit 99.2), both treated as furnished rather than filed under SEC rules.